By Sabela Ojea
Shares of United Therapeutics fell on pace for the largest percent decrease in three years after the company's fourth-quarter earnings fell short of expectations.
The stock was down 10%, to $321.90, in Wednesday trading. Shares are down 8.8% year to date, and have fallen 42% over the past 12 months.
The biotechnology company posted a net profit of $301.3 million, or $6.19 a share, compared with $217.1 million, or $4.36 a share, for the same period a year earlier. Analysts surveyed by FactSet had expected earnings of $6.40 a share.
Revenue rose 20%, to $735.9 million, offset by a 2.1% decline in Adcirca sales. Wall Street had expected revenue of $734.7 million, according to FactSet.
Adcirca is used to treat pulmonary arterial hypertension.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
February 26, 2025 12:08 ET (17:08 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。